## Véronique Bouvier

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10192133/publications.pdf

Version: 2024-02-01

109137 62479 9,610 82 35 80 citations h-index g-index papers 83 83 83 15502 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37â€^513â€`025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, The, 2018, 391, 1023-1075.	6.3	3,228
2	Global surveillance of cancer survival 1995–2009: analysis of individual data for 25â€^676â€^887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, The, 2015, 385, 977-1010.	6.3	1,863
3	International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncology, The, 2017, 18, 719-731.	5.1	992
4	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. European Journal of Cancer, 2015, 51, 2130-2143.	1.3	344
5	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	5.1	285
6	Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2191-2205.	1.3	205
7	Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89â€^828 children from 198 registries in 53 countries. Lancet Haematology,the, 2017, 4, e202-e217.	2.2	141
8	Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: Results from EUROCARE-5. European Journal of Cancer, 2015, 51, 2144-2157.	1.3	138
9	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5. European Journal of Cancer, 2015, 51, 2169-2178.	1.3	115
10	The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	1.3	97
11	On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2158-2168.	1.3	93
12	Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecologic Oncology, 2017, 144, 396-404.	0.6	93
13	The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecologic Oncology, 2017, 144, 405-413.	0.6	93
14	Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991â€"2010 (Automated Childhood Cancer Information System): a population-based study. Lancet Oncology, The, 2018, 19, 1159-1169.	5.1	85
15	Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time., 1997, 73, 220-224.		82
16	Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2206-2216.	1.3	82
17	Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2179-2190.	1.3	80
18	Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. European Journal of Cancer, 2015, 51, 2217-2230.	1.3	75

#	Article	IF	CITATIONS
19	Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2242-2253.	1.3	73
20	Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study. European Journal of Cancer, 2015, 51, 2120-2129.	1.3	66
21	Cancer Incidence and Survival in Adolescents and Young Adults in France, 2000–2008. Pediatric Hematology and Oncology, 2013, 30, 291-306.	0.3	60
22	Socioeconomic environment and cancer incidence: a French population-based study in Normandy. BMC Cancer, 2014, 14, 87.	1.1	57
23	Pancreatic cancer: Wait times from presentation to treatment and survival in a populationâ€based study. International Journal of Cancer, 2016, 139, 1073-1080.	2.3	57
24	A Population-based Comparison of Immunochemical Fecal Occult Blood Tests for Colorectal Cancer Screening. Gastroenterology, 2013, 144, 918-925.	0.6	56
25	Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2231-2241.	1.3	56
26	The effect of patient characteristics on second primary cancer risk in France. BMC Cancer, 2014, 14, 94.	1.1	53
27	Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Economics (United Kingdom), 2004, 13, 227-238.	0.8	48
28	Performance of immunochemical faecal occult blood test in colorectal cancer screening in averageâ€risk population according to positivity threshold and number of samples. International Journal of Cancer, 2009, 125, 1127-1133.	2.3	48
29	Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal of Epidemiology, 2020, 49, 1517-1525.	0.9	48
30	Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study. European Journal of Cancer, 2015, 51, 2254-2268.	1.3	47
31	Epidemiology of rare cancers and inequalities in oncologic outcomes. European Journal of Surgical Oncology, 2019, 45, 3-11.	0.5	47
32	Incidence and patterns of late recurrences in colon cancer patients. International Journal of Cancer, 2015, 137, 2133-2138.	2.3	46
33	Socioeconomic and healthcare supply statistical determinants of compliance to mammography screening programs: A multilevel analysis in Calvados, France. Cancer Epidemiology, 2010, 34, 309-315.	0.8	45
34	Could mobile mammography reduce social and geographic inequalities in breast cancer screening participation?. Preventive Medicine, 2017, 100, 84-88.	1.6	43
35	Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study. Preventive Medicine, 2016, 90, 52-58.	1.6	38
36	Digestive cancers and occupational asbestos exposure: incidence study in a cohort of asbestos plant workers. Occupational and Environmental Medicine, 2015, 72, 792-797.	1.3	32

#	Article	IF	Citations
37	Cancer incidence within a cohort occupationally exposed to asbestos: a study of dose-response relationships. Occupational and Environmental Medicine, 2011, 68, 832-836.	1.3	29
38	Treatment challenges in and outside a network setting: Soft tissue sarcomas. European Journal of Surgical Oncology, 2019, 45, 31-39.	0.5	27
39	Treatment challenges in and outside a network setting: Head and neck cancers. European Journal of Surgical Oncology, 2019, 45, 40-45.	0.5	27
40	Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial. Preventive Medicine, 2017, 103, 76-83.	1.6	25
41	Digestive and genitourinary sequelae in rectal cancer survivors andÂtheir impact on health-related quality of life: Outcome of a high-resolution population-based study. Surgery, 2019, 166, 327-335.	1.0	25
42	Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: Performances of immunochemical colorectal cancer screening. International Journal of Technology Assessment in Health Care, 2010, 26, 48-53.	0.2	24
43	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. European Journal of Surgical Oncology, 2019, 45, 67-74.	0.5	22
44	Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study. Cancer Epidemiology, 2019, 60, 106-111.	0.8	20
45	Colorectal cancer screening: Why immunochemical faecal occult blood test performs as well with either one or two samples. Digestive and Liver Disease, 2012, 44, 694-699.	0.4	19
46	Incidence and Patterns of Late Recurrences in Rectal Cancer Patients. Annals of Surgical Oncology, 2015, 22, 520-527.	0.7	18
47	Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial. Value in Health, 2018, 21, 685-691.	0.1	18
48	Trends in incidence of small bowel cancer according to histology: a population-based study. Journal of Gastroenterology, 2020, 55, 181-188.	2.3	17
49	Volume of surgical activity and lymph node evaluation for patients with colorectal cancer in France. Digestive and Liver Disease, 2012, 44, 261-267.	0.4	16
50	Socioeconomic status impacts survival and access to resection in pancreatic adenocarcinoma: A high-resolution population-based cancer registry study. Surgical Oncology, 2018, 27, 759-766.	0.8	16
51	Time-to-cure and cure proportion in solid cancers in France. A population based study. Cancer Epidemiology, 2019, 60, 93-101.	0.8	16
52	Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival. Journal of Adolescent and Young Adult Oncology, 2021, 10, 29-45.	0.7	16
53	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. European Journal of Surgical Oncology, 2019, 45, 75-80.	0.5	15
54	Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival $\hat{a} \in \text{``a registry-based study. BMC Health Services Research, 2021, 21, 1032.}$	0.9	15

#	Article	IF	CITATIONS
55	Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2876-2882.	0.6	13
56	Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population. European Journal of Gastroenterology and Hepatology, 2019, 31, 678-684.	0.8	13
57	Trends in the risk of second primary cancer among bladder cancer survivors: a populationâ€based cohort of 10 047 patients. BJU International, 2016, 118, 53-59.	1.3	12
58	Development of a model to predict the 10-year cumulative risk of second primary cancer among cancer survivors. Cancer Epidemiology, 2017, 47, 35-41.	0.8	11
59	No effect of comorbidities on the association between social deprivation and geographical access to the reference care center in the management of colon cancer. Digestive and Liver Disease, 2018, 50, 297-304.	0.4	11
60	Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. European Journal of Surgical Oncology, 2020, 46, 1151-1159.	0.5	9
61	†French LARS score': validation of the French version of the low anterior resection syndrome (LARS) score for measuring bowel dysfunction after sphincter-preserving surgery among rectal cancer patients: a study protocol. BMJ Open, 2020, 10, e034251.	0.8	9
62	Same Chance of Accessing Resection? Impact of Socioeconomic Status on Resection Rates Among Patients with Pancreatic Adenocarcinoma—A Systematic Review. Health Equity, 2021, 5, 143-150.	0.8	9
63	Effect of previous history of cancer on survival of patients with a second cancer of the head and neck. Oral Oncology, 2015, 51, 457-463.	0.8	8
64	Influence of social deprivation and remoteness on the likelihood of sphincter amputation for rectal cancer: a high-resolution population-based study. International Journal of Colorectal Disease, 2019, 34, 927-931.	1.0	8
65	Socioeconomic Environment and Survival in Patients with Digestive Cancers: A French Population-Based Study. Cancers, 2021, 13, 5156.	1.7	8
66	Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy. Digestive and Liver Disease, 2013, 45, 687-691.	0.4	7
67	Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities. Value in Health, 2019, 22, 1111-1118.	0.1	7
68	Survival of patients with cancer starting chronic dialysis: Data from kidney and cancer registries in lower Normandy. Nephrology, 2018, 23, 1125-1130.	0.7	6
69	What is the most appropriate period to define synchronous cancers?. Cancer Epidemiology, 2021, 71, 101900.	0.8	6
70	Management of rectal cancer in France in a well-defined population. European Journal of Gastroenterology and Hepatology, 2014, 26, 743-747.	0.8	5
71	Methodological issues of assessing the risk of a second cancer occurring in the same site as a first cancer using registry data. Cancer Epidemiology, 2017, 51, 41-43.	0.8	5
72	Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie. Journal of Nephrology, 2018, 31, 111-118.	0.9	5

#	Article	IF	CITATIONS
73	Has adherence to treatment guidelines for mid/low rectal cancer affected the management of patients? A monocentric study of 604 consecutive patients. Journal of Visceral Surgery, 2019, 156, 281-290.	0.4	5
74	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. European Journal of Surgical Oncology, 2019, 45, 60-66.	0.5	4
75	Seasonal variations of immunochemical and gaiac faecal occult blood tests. Gut, 2011, 60, 423-424.	6.1	3
76	Influence of a screening navigation program on social inequalities in health beliefs about colorectal cancer screening. Journal of Health Psychology, 2016, 21, 1700-1710.	1.3	3
77	Use of a case-mix approach to study the trends in the incidence of second primary cancers. Annals of Epidemiology, 2018, 28, 322-327.	0.9	3
78	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 46-51.	0.5	3
79	Influence of non-clinical factors on restorative rectal cancer surgery: An analysis of four specialized population-based digestive cancer registries in France. Digestive and Liver Disease, 2022, 54, 258-267.	0.4	3
80	Analysis of medico-social factors for return to work among patients presenting with haematological malignancy (adamantine): results of a †pilot study'. BMC Research Notes, 2020, 13, 313.	0.6	1
81	Association Between Use of Anticancer Drugs and Cardiovascular Disease–Related Hospitalization in Metastatic Colorectal Cancer: Insights From a Population-Based Study, the Anticancer Vigilance of Cardiac Events Study. American Journal of Epidemiology, 2021, 190, 376-385.	1.6	1
82	Re: Fecal Occult Blood Screening in the Minnesota Study. Journal of the National Cancer Institute, 1998, 90, 465-467.	3.0	0